What is the 13F Pro Quality Score for LUCD?

13F Pro ranks Lucid Diagnostics Inc. (LUCD) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View LUCD's current score at https://13fpro.ai/company/LUCD (free sign-up required for the full ranking).

Where does 13F Pro source LUCD data?

All Lucid Diagnostics Inc. fundamentals and ownership data come directly from SEC EDGAR. Lucid Diagnostics Inc. files with the SEC under CIK 1799011. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is LUCD in?

Lucid Diagnostics Inc. (LUCD) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is LUCD research updated on 13F Pro?

LUCD's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Lucid Diagnostics Inc.(LUCD)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1799011 LUCD stock profile & AI dashboard →

13F Pro Quality Score

29.5/100

Rank #2,528 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why LUCD Scores 30/100

exact factor attribution · 2026-09-11

LUCD's composite is driven by revenue growth and institutional flow, held back by free cash flow and scale. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+5.8 pts

79th pct

Institutional flow

+2.0 pts

90th pct

Earnings growth

+1.9 pts

88th pct

Shareholder dilution

-2.2 pts

6th pct

Earnings quality

-3.1 pts

19th pct

Capital efficiency

-4.8 pts

3th pct

Profitability

-6.7 pts

6th pct

Scale

-6.7 pts

6th pct

Free cash flow

-6.8 pts

5th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

LUCD Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Lucid Diagnostics Inc. (LUCD), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores LUCD at 29.5/100 on a 32-signal composite quality model, placing it at rank #2,528 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Lucid Diagnostics Inc. reports quarterly revenue of $1.5M, net income of $-11.7M, free cash flow of $-11.3M. Top institutional holders of LUCD by reported 13-F value include Alyeska Investment Group, L.P., BlackRock, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. LUCD trades on the Nasdaq exchange and files with the SEC under CIK 1799011. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LUCD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Lucid Diagnostics Inc. directly from SEC EDGAR. Lucid Diagnostics Inc.'s 13F Pro composite quality score has ranged between 20 and 30 since 2026, currently 29.5 — an improving long-term trajectory across 8 quarterly and live scoring snapshots.

Revenue

Q2 2026

$1.5M

Net Income

Q2 2026

$-11.7M

Free Cash Flow

Q2 2026

$-11.3M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+8.3% YoY

$4.7MFY 2025

FY22 $377.0KFY23 $2.4MFY24 $4.3MFY25 $4.7M

Net Income

-27.4% YoY

$-58.0MFY 2025

FY22 $-56.2MFY23 $-52.7MFY24 $-45.5MFY25 $-58.0M

Operating Income

-7.8% YoY

$-49.6MFY 2025

FY22 $-56.3MFY23 $-48.5MFY24 $-46.1MFY25 $-49.6M

EPS (Diluted)

—FY 2025

FY22 $-1.55FY23 $-1.26FY24 $-1.05FY25 —

Total Assets

+31.7% YoY

$40.4MFY 2025

FY22 $32.5MFY23 $27.3MFY24 $30.7MFY25 $40.4M

Total Debt

—FY 2025

FY22 —FY23 —FY24 —FY25 —

Op. Cash Flow

-5.3% YoY

$-46.5MFY 2025

FY22 $-29.7MFY23 $-32.8MFY24 $-44.1MFY25 $-46.5M

Free Cash Flow

-5.1% YoY

$-46.7MFY 2025

FY22 $-32.9MFY23 —FY24 $-44.4MFY25 $-46.7M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$4.7M +8.3%	$4.3M +79.0%	$2.4M +544.0%	$377.0K -24.6%	$500.0K	—
Net Income	$-58.0M -27.4%	$-45.5M +13.6%	$-52.7M +6.2%	$-56.2M -100.1%	$-28.1M -239.1%	$-8.3M
Operating Income	$-49.6M -7.8%	$-46.1M +5.0%	$-48.5M +13.8%	$-56.3M -105.2%	$-27.4M -231.1%	$-8.3M
EPS (Diluted)	—	$-1.05 +16.7%	$-1.26 +18.7%	$-1.55	—	—
Total Assets	$40.4M +31.7%	$30.7M +12.6%	$27.3M -16.1%	$32.5M -44.9%	$59.0M +2587.9%	$2.2M
Total Debt	—	—	—	—	—	$13.3M
Operating Cash Flow	$-46.5M -5.3%	$-44.1M -34.5%	$-32.8M -10.6%	$-29.7M -68.0%	$-17.7M -213.9%	$-5.6M
Free Cash Flow	$-46.7M -5.1%	$-44.4M	—	$-32.9M -77.5%	$-18.5M	—

Get alerted when LUCD's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Lucid Diagnostics Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of LUCD

Alyeska Investment Group, L.P.
$9.5M8,856,844 sh
BlackRock, Inc.
$9.0M8,373,117 sh
VANGUARD CAPITAL MANAGEMENT LLC
$7.0M6,556,344 sh
Two Seas Capital LP
$6.4M6,000,000 sh
MASTERS CAPITAL MANAGEMENT LLC
$4.3M4,000,000 sh
abrdn plc
$4.1M3,822,997 sh
GEODE CAPITAL MANAGEMENT, LLC
$4.1M3,789,948 sh
STATE STREET CORP
$2.6M2,437,337 sh
FIRST MANHATTAN CO. LLC.
$2.3M2,188,550 sh
WELLS FARGO & COMPANY/MN
$2.2M2,067,046 sh

Fund	Value	Shares
Alyeska Investment Group, L.P.	$9.5M	8,856,844
BlackRock, Inc.	$9.0M	8,373,117
VANGUARD CAPITAL MANAGEMENT LLC	$7.0M	6,556,344
Two Seas Capital LP	$6.4M	6,000,000
MASTERS CAPITAL MANAGEMENT LLC	$4.3M	4,000,000
abrdn plc	$4.1M	3,822,997
GEODE CAPITAL MANAGEMENT, LLC	$4.1M	3,789,948
STATE STREET CORP	$2.6M	2,437,337
FIRST MANHATTAN CO. LLC.	$2.3M	2,188,550
WELLS FARGO & COMPANY/MN	$2.2M	2,067,046

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put LUCD on your watchlist

Track score changes the day Lucid Diagnostics Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is LUCD a good stock to buy?

13F Pro's AI-powered analysis of Lucid Diagnostics Inc. (LUCD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for LUCD are available on the LUCD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. LUCD is classified as a small company.

Which hedge funds own LUCD?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling LUCD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Lucid Diagnostics Inc.'s investment landscape.